A Boxed Warning has been added to the label for Tofacitinib (Xeljanz XR), effective July 12, 2026. This significant label revision, considered the strongest warning the FDA requires, highlights serious risks associated with the drug. The updated warning specifically addresses potential for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis.
What this means
The addition of a Boxed Warning to the Xeljanz XR label, effective July 12, 2026, signifies critical safety considerations for prescribers and patients. This warning advises healthcare professionals of the potential for serious adverse events across several categories. The inclusion of SERIOUS INFECTIONS highlights the risk of opportunistic pathogens and other severe infections that may lead to hospitalization or death. The warning for MORTALITY indicates an increased risk of death in certain patient populations. Furthermore, the warning addresses MALIGNANCY, pointing to an elevated risk of certain cancers. The label also now includes warnings for MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), such as heart attack and stroke, and THROMBOSIS, encompassing deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis. These updates necessitate careful patient selection, thorough monitoring for symptoms of these serious conditions, and a comprehensive discussion of the risk-benefit profile with patients before and during treatment with tofacitinib. Clinicians are advised to consider these risks when prescribing Xeljanz XR, particularly in patients with pre-existing risk factors for cardiovascular disease, malignancy, or thrombosis. Patient counseling on the signs and symptoms of these serious risks is crucial for early detection and management.
Source
This information is based on an FDA label revision for Xeljanz XR (tofacitinib), effective July 12, 2026. The details are available on dailymed.nlm.nih.gov.